OKYO Pharma (NASDAQ:OKYO) completed full enrollment of patients in the randomized portion of the Phase 2 clinical trial of topical ocular, OK-101, to treat dry eye disease (DED). A total of 240 patients were enrolled in...
Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer...
Cantor Fitzgerald bolstered its healthcare and biotech equity research team with the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D. “Having two of the most highly regarded analysts in the biotechnology...
Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...
Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...
Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...
Plus Therapeutics (NASDAQ:PSTV) treated the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases (LM) from...
The board of Ampio Pharmaceuticals (NYSEA:AMPE) approved a 20-to-1 reverse stock split of the company’s common stock, to be effective at close on Sept. 11. Ampio’s common stock is expected to begin trading on a...
NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...
The FDA granted priority review designation for Zealand Pharma’s (NASDAQ:ZEAL; CVR-no. 20045078) dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients seven days of age and older with...